CD274 (PD-L1, B7-H1) Monoclonal Antibody (MIH1), PE-Cyanine7, eBioscience™, Invitrogen™

Description

• Description: The MIH1 monoclonal antibody reacts with human B7-H1, also known as PD-L1
• B7-H1, a member of the B7 family, has a predicted molecular weight of approximately 40 kDa and belongs to the Ig superfamily
• B7-H1 is expressed on a majority of leukocytes
• B7-H1 is a ligand for PD-1
• Interaction of PD-1 with either PD-L1 (B7-H1) or PD-L2 (B7-DC) results in inhibition of T and B cell responses
• MIH1 is reported to be a blocking antibody
• Applications Reported: This MIH1 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This MIH1 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells
• This can be used at 5 μL (0.25 μg) per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• Light sensitivity: This tandem dye is sensitive photo-induced oxidation
• Please protect this vial and stained samples from light
• Fixation: Samples can be stored in IC Fixation Buffer (cat
• 00-8222) (100 μL cell sample + 100 μL IC Fixation Buffer) or 1-step Fix/Lyse Solution (cat
• 00-5333) for up to 3 days in the dark at 4°C with minimal impact on brightness and FRET efficiency/compensation
• Programmed death receptor ligand 1 (PD-L1, also called B7-H1) is a recently described B7 family member
• To date, one specific receptor has been identified that can be ligated by PD-L1
• This receptor, programmed death receptor 1 (PD-1), has been shown to negatively regulate T-cell receptor (TCR) signaling
• Upon ligating its receptor, PD-L1 has been reported to decrease TCR-mediated proliferation and cytokine production
• PD-L1 expression was found to be abundant on many murine and human cancers and could be further up-regulated upon IFN-gamma stimulation
• Thus, PD-L1 might play an important role in tumor immune evasion.